These observations indicate that SVA elicits B and T cell activation early upon infection, with IgM antibody levels being associated with early neutralizing activity against the virus and peak B and T-cell responses paralleling with clinical resolution of the disease, suggesting that both arms of the immune system may contribute to the control of SVA infection. This evidence concerns the gene CD40LG and infection.